Antisense oligonucleotide specific for transforming growth factor-β1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer

Anticancer Research

Volumn 18, Issue 3 A, 1998, Pages 1585-1589

  Tzai, Tzong Shin ^a,b   Lin, Chu Ing ^a   Shiau, Ai Li ^a   Wu, Chao Liang ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antisense oligonucleotide; Bladder cancer; Transforming growth factor 1

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; FLUOROURACIL; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER INHIBITION; COLONY FORMATION; CONTROLLED STUDY; ELECTROPORATION; FEASIBILITY STUDY; FEMALE; GENE THERAPY; GENETIC TRANSFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT PLASMID; T LYMPHOCYTE;

ANIMALS; BASE SEQUENCE; CELL DIVISION; CELL LINE; FEMALE; GENE THERAPY; MICE; MICE, INBRED C3H; OLIGONUCLEOTIDES, ANTISENSE; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; URINARY BLADDER NEOPLASMS;

EID: 0031828490     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Wojtowicz-Praga S: Reversal of tumor-induced immunosuppression: A new approach to cancer therapy. J Immunother 20(3): 165-177, 1997.
2. Dhanani S, Huang M, Wang J and Dubinett SM : Interferon-alpha inhibits murine macrophage transforming growth factor-beta mRNA expression. Inflammation: 301-309, 1994.
3. Inge TH, Hoover SK, Susskind BM, Barrett SK and Bear HD: Inhibition of tumor-specific cytotoxic T-Lymphocyte responses by transforming growth factor β1. Cancer Res 52: 1386, 1992.
4. Kehrl JH: Transforming growth factor-β: an important mediator of immunoregulation. Int J Cell Cloning 9: 438-450, 1991.
5. Ruscett, FW and Palladino MA: Transforming growth factor-β and the immune system. Progr. Growth Factor Res 3: 159-175, 1991.
6. Torre-Amione G and Beanchamp RDA: A highly immunogenic tumor transfected with murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87: 1486-1490, 1990.
7. Miyamoto H, Kubota Y, Shuin T, Torigoe S, Dobashi Y and Hosaka M: Expression of transforming growth factor-beta1 in human bladder cancer. Cancer 75: 2565-2570, 1995.
8. Coombs LM, Pigott DA, Eydmann ME, Proctor AJ and Knowles MA: Reduced expression of TGFβ is associated with advanced disease in transitional cell carcinoma. Br J Cancer 67: 578-584, 1993.
9. Tzai TS, Shiau AL, Lin CS, Wu CL and Lin JSN: Modulation of immunostimulating effect of autologous tumor vaccine by anti-TGF-β antibody and interferon-α on murine MBT-2 bladder cancer. Anticancer Res 17: 1073-1078, 1997.
10. Perez JR, Higgins-Sochaski KA, Maltese JY and Narayanan R: Regulation of adhesion and growth of fibrosarcoma cells by NF-kB RelA involves transforming growth factor β. Mol Cell Bio 14: 5326-5332, 1994.
11. Spearman M, Taylor WR, Greenberg AH and Wright JA: Antisense oligodeoxyribonucleotide inhibition of TGF-beta 1 gene expression and alterations in the growth and malignant properties of mouse fibrosarcoma cells. Gene 149(1): 25-29, 1994.
12. Wojtowicz-Praga S, Verma UN, Wakefield L, Esteban JM, Hartmann D and Mazumder A: Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. J Immunother Empahsis Tumor Immunol 19(3): 169-175, 1996.
13. Ruscetti FW and Palladino MA: Transforming growth factor-beta and the immune system. Progress in Growth Factor Research 3(2): 159-175, 1991.
14. Koff A, Ohtsuki M, Polyak K, Robert JM and Massagne J: Negative regulation of G1 in mammalian cells: Inhibition of cyclin E-dependent kinase by TGF-β. Science (Washington DC), 260: 536-539, 1993.
15. Ewen ME, Sluss HK, Whitehouse LL and Livingston DM: TGF β inhibition of cdk4 synthesis is linked to cell cycle arrest. Cell 74: 1009-1020, 1993.
16. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL and Robinson BW: Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 11(1): 29-44, 1994.
17. Arrick BK, Lopez AR, Elfman F, Ebner R, Damsky CH, and Derynck R: Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor β1. J Cell Biol 118: 715-726, 1992.
18. Ueki N, Nakazoto M, Ohkawa T, Ikeda T, Amuro Y, Hada T and Higashino K: Excessive production of transforming growth-factor β1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim Biophys Acta 1137: 189-196, 1992.
19. Chang H-L, Gillett N, Figari I, Lopez AR, Palladino MA and Derynck R: Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of meth A sarcoma cells. Cancer Res 53: 4391-4398, 1993.
20. Steiner MS: Transforming growth factor-β and prostate cancer. World J Urol 13: 329-336, 1995.
21. Moses HL, Yang EY, Pietenpol JA: TGF-β stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63: 245-247, 1990.
22. Robert AB, Thompson NC, Heine U, Flanders C and Sporn MB: Transforming growth factor β: possible roles in carcinogenesis. Br J Cancer 57: 594-600, 1988.
23. Marzo AL, Fitzpatrick DR, Robinson BW and Scott B: Antisense oligonucleotides specific for transforming growth factor beta 2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 57(15): 3200-3207, 1997.